Protein Inhibitors Global Market Report 2024

The protein inhibitors market size has grown strongly in recent years. It will grow from $80.99 billion in 2023 to $88.74 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. Historical growth in the field of protein inhibitors can be primarily attributed to advancements in drug discovery and development, particularly in cancer treatment. Additionally, the attainment of regulatory approvals for these inhibitors played a pivotal role in their historical growth trajectory. The ongoing efforts in drug discovery and development, coupled with successful regulatory clearances, significantly contributed to the progress and expansion observed in the historic period within the domain of protein inhibitors.

The protein inhibitors market size is expected to see strongly grown in the next few years. It will grow to $125.26 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. Anticipated growth in the upcoming period is linked to various factors, including the advancement of precision medicine, the increasing prominence of immunotherapy, the exploration of drug combinations, and the expanding aging population's healthcare needs.

The expanding prevalence of chronic diseases worldwide, encompassing conditions like cancer, cardiovascular issues, and autoimmune disorders, is poised to significantly drive the protein inhibitors market. Chronic diseases are projected to become a prominent global cause of mortality by 2030, reaching an alarming 157 million cases in the US alone by 2020. Protein inhibitors stand as pivotal treatments for such diseases, offering heightened efficacy and fewer adverse effects. Hence, the burgeoning population affected by chronic ailments is anticipated to fuel the demand for protein inhibitors, contributing to market growth.

The surging demand for personalized medicine is set to be a major catalyst propelling the protein inhibitors market. Personalized medicine, tailored to an individual's genetic composition, promises more precise and effective medical interventions. Protein inhibitors play a vital role in this domain by targeting specific proteins in alignment with an individual's genetic profile for disease treatment. Notably, a significant percentage of new molecular entities approved by the FDA in 2022, almost 34% fall under the category of personalized medicines, signifying the rising demand and adoption of such treatments. This surge directly drives the expansion of the protein inhibitors market. Companies invested in the protein inhibitors market are strategically engaging in partnerships and collaborations to drive drug development and meet market demands. Collaborative ventures and partnership agreements serve as avenues for expanding product portfolios and market presence. A prime example involves Eli Lilly and Company joining forces with Rigel Pharmaceuticals, Inc. In February 2021, entering a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, targeting autoimmune and inflammatory diseases among other indications.

Key players in the protein inhibitors market are prioritizing the development of tyrosine kinase 2 (TYK2) inhibitors, positioning themselves competitively. TYK2 inhibitors, instrumental in treating specific autoimmune conditions by blocking the TYK2 enzyme involved in immune system responses, are a significant focus. For instance, Bristol-Myers Squibb Company gained FDA approval in September 2022 for Sotyktu (deucravacitinib), an oral medication specifically for adults with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. Sotyktu stands as the first oral treatment with selective inhibition of TYK2 through allosteric mechanisms, marking a significant advancement in this segment of the market.

In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus.

Major companies operating in the protein inhibitors market include Bayer AG, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Novartis International AG, GlaxoSmithKline PLC, Pfizer Inc., Boehringer Ingelheim International GmbH, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc., Interprotein Corporation, AbbVie Inc., Bristol Myers Squibb Company, Galapagos NV, Priovant Therapeutics Inc., Tempus Labs Inc., ReCode Therapeutics Inc., Satellite Bio Inc., Ambagon Therapeutics Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Inc., Lonza Group AG, Catalent Inc., Thermo Fisher Scientific Inc., Charles River Laboratories International Inc., WuXi AppTec Co. Ltd.

North America was the largest region in the protein inhibitors market in 2023. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary types of protein inhibitors include protein kinase inhibitors, monoclonal antibodies, and other related compounds. Monoclonal antibodies, created in laboratories, mimic or enhance the immune system's attack on unwanted cells, such as cancer cells, effectively acting as substitute antibodies. These protein inhibitors find application in treating conditions like oncology (cancer) and inflammatory diseases. They are distributed through various channels including hospital pharmacies, independent pharmacies, and online pharmacies to reach patients in need of these treatments.

The protein inhibitors market research report is one of a series of new reports provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.